Insiders Aren’t Buying Pfizer Stock, and That Could Help
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Identify a reliable starting point by focusing on liquidity, security, and real-world use cases that resonate with new investors.
23,507 articlesPfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
IonQ shows a real enterprise backlog totaling hundreds of millions, while Rigetti burns cash with declining revenue. ...
A wrist-worn hormone monitor backed by a $11 million seed round aims to turn hormone tracking into everyday wellness....
CFOs say U.S. firms rode out oil-driven energy costs, but fears of ongoing inflation and a slower economy are rising....
Tapestry, the company behind Coach and Kate Spade, blends capital planning with daily operations to decide which bran...
A European intelligence report warns that russia’s economy ‘illusion’ built on debt may crumble as a banking crisis l...
A California court ruling affecting a rival studio triggered a risk-off mood that pulled down entertainment names, in...
A senior EU lawmaker is pushing to pause ratification of a major transatlantic trade pact as tariff chaos rattles mar...
A rumored $111 billion Paramount Warner Bros' deal could fuse studios, streaming, and networks under a private group,...
2025 delivered a record surge in corporate giving and volunteerism, signaling a durable pivot in corporate activism d...
Carvana, known for online used-car sales, is making a curious bet on Stellantis. This article explains the rationale,...
A fresh study links Gen Z’s straight‑A trend to lower long‑term earnings, signaling hidden costs behind perfect repor...